ホーム › 膀胱癌 › オクラホマ › Oklahoma City
Oklahoma City、OKにおける膀胱癌の臨床試験
Oklahoma Cityとその周辺地域（約30マイル以内）の拠点で、膀胱癌に関する11件の研究が参加者を募集しています。研究を開いて、参加資格と連絡方法を確認してください。
公式研究テキスト（英語）
ここで研究参加者を募集していますか？ このページの上部に表示できます — 30日間 $99 →
Testing the Addition of an Anti-Cancer Drug, Gemcitabine, to Usual Treatment (BCG Alone) in People Whose Non-Muscle Invasive Bladder Cancer (NMIBC) Came Back After Prior BCG Therapy
被験者募集中第3相
- University of Oklahoma Health Sciences Center, Oklahoma City
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
被験者募集中観察研究健康なボランティア歓迎
- Mercy Hospital Oklahoma City, Oklahoma City
Testing the Addition of the Immunotherapy Drug, Pembrolizumab, to Radiation Therapy Compared to the Usual Chemotherapy Treatment During Radiation Therapy for Bladder Cancer, PARRC Trial
被験者募集中第2相
- University of Oklahoma Health Sciences Center, Oklahoma City
Combining Immunotherapy and Radiation Therapy to Help Patients Avoid Bladder Removal After Treatment Shrinks Muscle Invasive Bladder Cancer, BRIGHT Trial
被験者募集中第2相
- University of Oklahoma Health Sciences Center, Oklahoma City
Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors
被験者募集中第2相
- University of Oklahoma Health Sciences Center, Oklahoma City
The Vanguard Study: Testing a New Way to Screen for Cancer
被験者募集中健康なボランティア歓迎
- University of Oklahoma Health Sciences Center, Oklahoma City
FORAGER-1: A Study of Vepugratinib (LY3866288; LOXO-435) in Participants With Cancer With a Change in a Gene Called FGFR3
被験者募集中第1相
- University of Oklahoma - Health Sciences Center, Oklahoma City
Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients Receiving the Usual Chemotherapy Treatment for Bladder Cancer, ARCHER Study
被験者募集中第3相
- University of Oklahoma Health Sciences Center, Oklahoma City
- Mercy Hospital Oklahoma City, Oklahoma City
A Study of Disitamab Vedotin Alone or With Pembrolizumab in Urothelial Cancer That Expresses HER2
被験者募集中第2相
- OU Health Stephenson Cancer Center, Oklahoma City
- OU Medical Center, Oklahoma City
A Study of Sigvotatug Vedotin in Advanced Solid Tumors
被験者募集中第1相
- OU Health University of Oklahoma Medical Center, Oklahoma City
- Stephenson Cancer Center (chemo location), Oklahoma City
- University of Oklahoma Health Science Center, Oklahoma City
Predicting Response to Immunotherapy From Analysis of Live Tumor Biopsies (ELEPHAS-05)
被験者募集中観察研究
- Mercy Hospital - OKC, Oklahoma City
他の都市における膀胱癌の試験
- New York City, NY35件の研究
- Nashville, TN31件の研究
- Houston, TX31件の研究
- Dallas, TX27件の研究
- Boston, MA26件の研究
- Washington, DC26件の研究
- Los Angeles, CA24件の研究
- Baltimore, MD24件の研究
- St. Louis, MO22件の研究
- Philadelphia, PA21件の研究
- Seattle, WA21件の研究
- Edison, NJ21件の研究
Oklahoma Cityにおける他の研究
- 非小細胞肺癌28件の研究
- 卵巣がん28件の研究
- 子宮内膜がん25件の研究
- 大腸癌22件の研究
- 前立腺がん21件の研究
- 肺がん19件の研究
- 乳がん17件の研究
- 転移性癌15件の研究
- がん（全種類）14件の研究
- 急性骨髄性白血病14件の研究
- 頭頸部扁平上皮癌13件の研究
- 膵臓がん11件の研究
ClinicalTrials.govより、2026/10/05時点のデータを取得。各研究には独自の参加資格があり、参加可否は研究チームが決定します。